Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin Corporation has filed a patent infringement lawsuit against Hikma Pharmaceuticals for allegedly infringing on three U.S. patents related to VASCEPA, a prescription drug intended for reducing cardiovascular risk.
The lawsuit, initiated in the United States District Court in Delaware, claims Hikma engaged in unlawful activities by making and selling generic icosapent ethyl capsules. Amarin seeks monetary damages and a permanent injunction to stop Hikma's actions, asserting its rights to intellectual property developed over a decade.
Amarin Corporation plc (NASDAQ:AMRN) announced that CEO John F. Thero will participate in a Fireside Chat at the Piper Sandler’s 32nd Annual Healthcare Conference from December 1-3, 2020. Thero's presentation is set for December 2, 2020, at 10:00 AM ET. A live audio webcast of the session will be available on Amarin's website and accessible for 30 days. Amarin focuses on developing therapeutics to improve cardiovascular health, with its lead product, VASCEPA® (icosapent ethyl), approved in select countries.
Amarin Corporation (NASDAQ:AMRN) announced positive results from the Phase 3 clinical trial EDPC003R01, assessing VASCEPA (icosapent ethyl) in Chinese patients with very high triglyceride levels (≥500 mg/dL). The trial demonstrated a statistically significant median triglyceride reduction of 19.9% with a 4 grams per day dosage, without increasing low-density lipoprotein cholesterol (LDL-C). The results support upcoming regulatory submission by Amarin's partner, Edding, for VASCEPA's approval in China, addressing a significant medical need amidst rising hypertriglyceridemia rates.
Amarin Corporation (NASDAQ:AMRN) presented new data on VASCEPA (icosapent ethyl) at the AHA Virtual Scientific Sessions 2020, reinforcing its effectiveness in reducing major adverse cardiovascular events (MACE) in high-risk patients. Key findings include the unique mechanism of action of eicosapentaenoic acid (EPA) and significant outcomes from the REDUCE-IT trial demonstrating a 24% reduction in MACE for patients with a history of coronary artery bypass grafting. The data supports VASCEPA's cost-effectiveness and its potential for broader use in preventive cardiovascular care.
Amarin Corporation reported significant advancements in the clinical efficacy of VASCEPA® at the AHA Virtual Scientific Sessions 2020. The REDUCE-IT CABG analysis showed a 24% reduction in primary composite major adverse cardiovascular events (MACE) and a 31% decrease in hard MACE among patients with a history of coronary artery bypass grafting (CABG). The absolute risk reductions were 6.2% and 6.0%, with numbers needed to treat of 16 and 17. The data supports VASCEPA's potential role in alleviating risks associated with CABG procedures.
Amarin Corporation, listed on NASDAQ as AMRN, has announced that CEO John F. Thero will present at two upcoming investor conferences in November 2020. The presentations are scheduled for:
- Stifel 2020 Virtual Healthcare Conference on November 16 at 8:40 a.m. ET
- Jefferies Virtual London Healthcare Conference on November 19 at 9:40 a.m. ET
Live audio webcasts will be available on Amarin's website for 30 days. The company is focused on improving cardiovascular health, with its lead product, VASCEPA, currently available in select countries.
Amarin Corporation (NASDAQ: AMRN) reported a significant increase in revenue, with Q3 2020 total revenue up by 39% to $156.5 million and a 56% increase in revenue for the first nine months, totaling $446.8 million, compared to 2019. Despite challenges from the COVID-19 pandemic, VASCEPA's prescription growth also surged, aided by direct-to-consumer advertising. The company is preparing for VASCEPA's European approval, expected in early 2021, while maintaining a robust cash reserve of $608 million. However, the company's net loss increased to $6.8 million for Q3 2020, impacted by rising SG&A expenses.
Amarin Corporation plc (NASDAQ:AMRN) will showcase new research on VASCEPA® (icosapent ethyl) during the AHA Virtual Scientific Sessions 2020 from November 13-17, 2020. Eight presentations will cover significant findings, including the 'REDUCE-IT CABG' results, highlighting the drug's efficacy in reducing major adverse cardiovascular events. Key insights reveal mechanisms of action and clinical outcomes, emphasizing VASCEPA’s role in managing cardiovascular risk in at-risk populations. These findings are expected to enhance understanding and application of icosapent ethyl in clinical settings.
Amarin Corporation presented the REDUCE-IT RENAL results at ASN Kidney Week 2020, highlighting VASCEPA's effectiveness in patients with compromised renal function. Patients with decreased renal function experienced higher cardiovascular event rates but showed significant risk reductions with VASCEPA compared to placebo. The study analyzed the impact across various eGFR categories, revealing consistent benefits in cardiovascular outcomes. Despite increased event rates with impaired renal function, VASCEPA maintained a favorable safety profile. The need for solutions addressing cardiovascular risks in chronic kidney disease remains crucial.
Amarin Corporation plc (NASDAQ:AMRN) presented new real-world data at the American Society of Nephrology Kidney Week 2020, highlighting the link between elevated triglyceride (TG) levels and increased cardiovascular (CV) risk. The analysis, conducted by the U.S. Department of Veterans Affairs, included 152,266 veterans with low-density lipoprotein (LDL)-cholesterol levels managed by statins. Results indicated that 29% of these patients had elevated TG levels and experienced higher rates of major adverse cardiovascular events, reinforcing TG levels as an independent risk factor for CV events in high-risk patients.